Date and Time
Thursday, February 2nd, 2017
8:00 AM - 10:00 AM CST
DoubleTree Minneapolis North
2200 Freeway Blvd
Minneapolis, MN 55430
The Health Value Series is presented by Deloitte and The Medical Alley Association.
Europe is considered a challenging environment for innovation of medical technologies. Budgets are under continued pressure and the long-term benefits of device innovation can be insufficiently recognized. There is perception of little political commitment to support the introduction of innovation into local health care systems in a meaningful way. So how do firms breakthrough?
This panel will discuss:
- Key trends impacting the pricing and reimbursement landscape in Europe
- Support for innovation from EU Member States versus other countries
- Opportunities to build transparency and predictability in investments in new technologies and the emergence of managed entry agreements.
- The role of real-world evidence, partnerships and new financing models in advancing innovation
Jonathan Brenner, Senior Director, Market Access, Bayer HealthCare
Jonathan Brenner is Senior Director, Market Access, in Bayer Pharmaceutical’s Radiology business. He is responsible for developing solutions for healthcare financial stakeholders, leading reimbursement, healthcare policy and health economics. He has worked for Bayer since 2011 leading global and regional market access. Previously Jonathan held market access roles of increasing responsibility at Zimmer, 3M Healthcare and St. Jude Medical. Jonathan has nearly 20 years of experience in policy and economics and since 2004 has developed solutions for healthcare financial stakeholders, protected and attained reimbursement in Europe, Asia and the Americas. Jonathan earned a BA in political science, summa cum laude, and an MBA in strategy from Washington University in St. Louis. He is a member of the Board of Directors of The Pediatric Device Innovation Consortium.
Stelios I. Tsintzos, MD MSc, Senior Manager - Global Health Economics and Outcomes Research
Dr. Tsintzos had been leading Reimbursement and Market Access efforts internationally for almost a decade. During his tenure in Medtronic, he initially led the European Reimbursement effort for Medtronic's implantable cardiac monitors and AF ablation catheters. Alongside economic research, Dr. Tsintzos achieved positive UK NICE clinical guidance for syncope monitoring and played a critical role to the outcome of the Belgian KCE appraisal of Catheter Ablation for AF. For the last 5 years, he is holding a global role in developing economic value evidence for the HF business of Medtronic. Dr. Tsintzos began his career as a Management Consultant in the Government and Public Sector Advisory Service Line of PwC UK and holds an MD from the University of Ioannina, and an MSc from the London School of Economics.
Moderator: R. Ömer Saka MD MSc, Partner, Market Access Strategy and Health Economics Group, Monitor Deloitte
Ömer is a qualified medical doctor who is an expert on public health, health economics, policy and management, working in the field of health economics and outcomes research for over 10 years.
Omer currently is leading the Life Sciences and HEOR practice in Deloitte Belgium which provides services to the external (GSK-Biologicals, Bayer, Boehringer Ingelheim, J&J, Eli Lilly) and internal (Global Deloitte) clients as the centre of excellence on HEOR.
He has been involved in public health since his student years being the Director of Public Health of the International Federation of Medical Students Associations. During this time he worked closely with organizations such as the WHO, UNICEF, UNESCO and the World bank.
After graduating from medical school he worked for two years for a health policy and management consultancy company. In the mean time he obtained his MSc degree from the LSE on health policy planning and financing. He worked in academia for 5 years at the LSE and King’s College, London and provided teaching on health technology assessment modelling methods, supervised thesis, published in peer reviewed journals and was involved a number of consultancy projects for governmental organisations (EU, UK, Turkey, Germany, South Korea) and pharmaceutical industry (Including consulting to Genzyme’s on Cerezyme and health technology assessment methods of Orphan drugs). Later he joined the National Audit Office of England to lead the health economics and decision modelling practices in that organization.